Actively Recruiting
Stereotactic Radiotherapy (SBRT) of Lung Metastasis
Led by University Health Network, Toronto · Updated on 2026-03-06
200
Participants Needed
1
Research Sites
1122 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
P
Princess Margaret Hospital, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up. SBRT has been in clinical use for over a decade in some institutions and the available data suggest that it can be used safely and with good results. This study will see how effective Stereotactic Body Radiation Therapy is for treating tumours in the lung and how often people have side effects. Radiation therapy is usually given once a day, often for a few weeks. In this study, study participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks. Several reports indicate that this therapy might shrink tumours and control the cancer for extended periods of time. Although specialists started to treat patients with SBRT over 10 years ago, it is still used in relatively few cancer centres.
CONDITIONS
Official Title
Stereotactic Radiotherapy (SBRT) of Lung Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological confirmation of malignancy unless biopsy is too risky and lesion shows growth on CT or PET positivity
- Stage I or II non-metastatic non-small cell lung cancer (specific tumor stages) or controlled non-lung primary cancer with lung-only metastases
- Patients with limited metastatic lung tumors who may benefit from high-dose SBRT
- Patients with potentially resectable disease considered medically inoperable or surgery not preferred
- For early stage lung cancer, up to 3 lung lesions; for metastatic lung disease, up to 5 lung lesions
- Early stage primary NSCLC patients must have no clinical or radiological evidence of lymph node spread
- Co-existing malignancy must have a better prognosis than lung cancer if present
- Adequate lung function to tolerate stereotactic radiation
- Previous conventional radiotherapy to mediastinum/lung allowed if SBRT unlikely to impair lung function
- At least 18 years old
- Zubrod performance status between 0 and 3
- Women of childbearing potential and men must use effective contraception
- Willing and able to provide informed consent
You will not qualify if you...
- Active systemic, pulmonary, or pericardial infection
- Receiving concurrent systemic therapy other than hormone therapy
- History of active autoimmune diseases such as lupus, rheumatoid arthritis, systemic sclerosis, or scleroderma
- Candidate for concurrent chemo-radiation therapy
- Enrollment in other studies depends on patient and study characteristics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Hospital, University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
J
John Cho, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here